Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

65.95 -0.12 (-0.18%)
Official Closing Price Updated: 4:15 PM EDT, Jul 1, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,528,581
Open 64.10
Bid (Size) 64.26 (7)
Ask (Size) 66.26 (1)
Prev. Close 66.07
Today's Range 64.06 - 65.97
52wk Range 53.63 - 71.70
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
AstraZeneca Shares Data at EASL and ESMO World GI for IMFINZI® (durvalumab) Combinations in Patients With Liver and Biliary Tract Cancers
From AstraZeneca
Via Business Wire
The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga

Performance

YTD
+13.10%
+13.10%
1 Month
-0.26%
-0.26%
3 Month
-1.29%
-1.29%
6 Month
+13.22%
+13.22%
1 Year
+9.35%
+9.35%

More News

Read More
FDA Expert Panel Favors COVID-19 Boosters Targeting Omicron BA.4, BA.5 Subvariants
Via Benzinga
Benzinga Before The Bell: Kohl's Deal Talks Cancellation, Tesla's Racial Discrimination Lawsuit, Nio's Strong June Deliveries And Other Top Financial Stories Friday, July 1
Via Benzinga
Short Volatility Alert: AstraZeneca PLC
Via Benzinga
Oxford Biomedica Inks New Three Year Deal To Make AstraZeneca's COVID-19 Vaccine
Via Benzinga
The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial
Via Benzinga
AstraZeneca Says Imfinzi/Chemo Combo Shows Promising Action In Late-Stage Lung Cancer Study
Via Benzinga
IMFINZI® (durvalumab) Plus Chemotherapy Significantly Improved Pathologic Complete Response in AEGEAN Phase III Trial in Resectable Non-Small Cell Lung Cancer
From AstraZeneca Pharmaceuticals
Via Business Wire
7 Beaten-Down S&P 500 Stocks to Buy Before They Rebound
Via InvestorPlace
Akebia Therapeutics (AKBA) Stock Soars 18% Despite Lack of News
Via InvestorPlace
AstraZeneca Whale Trades For June 29
Via Benzinga
The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
Via Benzinga
EMA's Advisory Committee Backs Approval For AstraZeneca's Targeted Breast Cancer Therapies
Via Benzinga
Week In Review: InvoX, A Sino Biopharma Company, To Pay $161 Million To Acquire F-Star
Via Talk Markets
What Are Whales Doing With AstraZeneca
Via Benzinga
AstraZeneca's ALXN1840 Shows Promising Action Against Copper Metabolism Disorder
Via Benzinga
ALXN1840 Shows Rapid and Sustained Improvement in Copper Mobilization From Tissues, Potentially Closing Treatment Gaps for Wilson Disease Community
From Alexion
Via Business Wire
Economic Hurricane Ahead? 7 Profitable Places to Hide Your Money
Via InvestorPlace
7 Blue-Chip Stocks to Buy and Hold for the Long-Haul
Via InvestorPlace
The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial
Via Benzinga
AstraZeneca - Ionis Eplontersen Achieves Positive Data In Rare Disease Trial
Via Benzinga
PROpel Phase III Trial Positive Results of LYNPARZA® (olaparib) Plus Abiraterone in 1st-line Metastatic Castration-resistant Prostate Cancer Published in New England Journal of Medicine Evidence
From AstraZeneca
Via Business Wire
Eplontersen Met Co-Primary and Secondary Endpoints in Interim Analysis of the NEURO-TTRansform Phase III Trial for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (ATTRv-PN)
From AstraZeneca
Via Business Wire
Dow Jones Erased Gains Late in the Day, as Investors Continued to Consider Fears About Sluggish Economic Is Growth.
Via Best Stocks
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.